IN2014DN01822A - - Google Patents

Info

Publication number
IN2014DN01822A
IN2014DN01822A IN1822DEN2014A IN2014DN01822A IN 2014DN01822 A IN2014DN01822 A IN 2014DN01822A IN 1822DEN2014 A IN1822DEN2014 A IN 1822DEN2014A IN 2014DN01822 A IN2014DN01822 A IN 2014DN01822A
Authority
IN
India
Prior art keywords
relates
present
protease inhibitor
conjugates
conjugated
Prior art date
Application number
Inventor
Colin Watts
Sander Van Kasteren
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of IN2014DN01822A publication Critical patent/IN2014DN01822A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1808Epidermal growth factor [EGF] urogastrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8142Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a multi functional protease inhibitor which may be conjugated to various molecules. The present invention also relates to uses of the protease inhibitor and conjugates thereof
IN1822DEN2014 2011-08-15 2012-08-15 IN2014DN01822A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1114017.5A GB201114017D0 (en) 2011-08-15 2011-08-15 Inhibitors against endosomal/ysosomal enzymes
PCT/GB2012/000660 WO2013024243A1 (en) 2011-08-15 2012-08-15 Inhibitors against endosomal/lysosomal enzymes

Publications (1)

Publication Number Publication Date
IN2014DN01822A true IN2014DN01822A (en) 2015-05-15

Family

ID=44764498

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1822DEN2014 IN2014DN01822A (en) 2011-08-15 2012-08-15

Country Status (6)

Country Link
US (1) US9050374B2 (en)
EP (1) EP2744821B1 (en)
CN (1) CN103814046B (en)
GB (1) GB201114017D0 (en)
IN (1) IN2014DN01822A (en)
WO (1) WO2013024243A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311909A (en) * 2015-08-13 2024-06-01 Takeda Pharmaceuticals Co Method for assesing the level of drug targeting the contact system in a subject
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1066315B1 (en) * 1998-03-26 2008-05-28 University of Dundee Use of inhibitors of mammalian asparaginyl endopeptidase for modulating the immune system
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease

Also Published As

Publication number Publication date
CN103814046B (en) 2017-05-17
EP2744821A1 (en) 2014-06-25
CN103814046A (en) 2014-05-21
WO2013024243A1 (en) 2013-02-21
US9050374B2 (en) 2015-06-09
GB201114017D0 (en) 2011-09-28
EP2744821B1 (en) 2016-12-07
US20140308318A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
SG195196A1 (en) Dual targeting
EP4223770A3 (en) Novel fusion molecules and uses thereof
MX345514B (en) Pesticidal compositions.
UA114611C2 (en) PESTICIDIC COMPOSITIONS AND METHODS RELATING TO THEM
BR112012025645A2 (en) high mannose glycans.
MX340831B (en) Pesticidal compositions.
WO2013022996A9 (en) The utility of nematode small molecules
BR112013007362A2 (en) pharmaceutical composition
EP2638521A4 (en) Targeting based on intent or presence
BR112014001219A2 (en) perfume
GB201103836D0 (en) Conjugation process
UA114655C2 (en) Pyridine-2-amides useful as cb2 agonists
EP2632895A4 (en) Hiv protease inhibitors
MY161868A (en) Anti-bv8 antibodies and uses thereof
EP2435037A4 (en) Hiv protease inhibitors
UA112760C2 (en) THEOBROMIN IN COMBINATION WITH GUYPHENESINE FOR THE TREATMENT OF Cough
CL2009001973S1 (en) Counter.
WO2014052713A3 (en) Her2-and vegf-a-binding proteins with enhanced stability
IN2014DN01822A (en)
EA201391563A1 (en) SOLID MATTER POLYCHLOROPRENE WITH TIXOTROPIC PROPERTIES
HK1151718A1 (en) Flupentixol compositions
BR112013032223A2 (en) isolated nucleic acid molecule and composition
PL2306995T3 (en) Antitumor properties of no modified protease inhibitors
MX2015006616A (en) Dual targeting.
IN2014DN00168A (en)